title: The proportion of lymphocytic inflammation with CD123-positive cells in lupus erythematous profundus predict a clinical response to treatment.
abstract: Lupus erythematosus profundus is a rare inflammatory disorder of subcutaneous fat in patients with lupus ery-thematosus. Previous reports suggested that plasmacytoid dendritic cells, which expressed CD123 and CD303 antigens, play a central proinflammatory role in the patho-genesis of lupus erythematosus. To find the factors that determine the response to treatment, we analysed 23 skin specimens from the patients with lupus erythematosus profundus. The patients with considerable lymphocytic inflammation with high percentages of CD123+ cells in dermis and subcutaneous fat significantly responded to the systemic corticosteroid therapies. On the other hand, the patients with minor lymphocytic inflammation with low percentages of CD123+ cells showed poor response to treatments. The mean percentage of CD123+ cells in patients who showed good response to therapy was significantly higher than those that showed poor response (p = 0.027). These results suggest that the clinical response to treatment of lupus erythematosus profundus could be predicted from the histological features.
authors.affiliation: Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, Japan.
authors.forename: Azusa
authors.initials: A
authors.lastname: Miyashita
authors.forename: Satoshi
authors.initials: S
authors.lastname: Fukushima
authors.forename: Takamitsu
authors.initials: T
authors.lastname: Makino
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Yoshino
authors.forename: Junji
authors.initials: J
authors.lastname: Yamashita
authors.forename: Noritoshi
authors.initials: N
authors.lastname: Honda
authors.forename: Jun
authors.initials: J
authors.lastname: Aoi
authors.forename: Asako
authors.initials: A
authors.lastname: Ichihara
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Jinnin
authors.forename: Yuji
authors.initials: Y
authors.lastname: Inoue
authors.forename: Hironobu
authors.initials: H
authors.lastname: Ihn
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D020405:Dermis / Q000378:metabolism / Q000473:pathology; D005260:Female; D019085:Fluorescent Antibody Technique, Direct; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007150:Immunohistochemistry; D053650:Interleukin-3 Receptor alpha Subunit / Q000378:metabolism*; D008214:Lymphocytes / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D015435:Panniculitis, Lupus Erythematosus / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D050151:Subcutaneous Fat / Q000378:metabolism / Q000473:pathology; D055815:Young Adult
chemical_list: D005938:Glucocorticoids; D053650:Interleukin-3 Receptor alpha Subunit